Ventyx Biosciences, Inc. – NASDAQ:VTYX

Ventyx Biosciences stock price today

$2.58
+0.20
+8.4%
Financial Health
0
1
2
3
4
5
6
7
8
9

Ventyx Biosciences stock price monthly change

-7.03%
month

Ventyx Biosciences stock price quarterly change

-7.03%
quarter

Ventyx Biosciences stock price yearly change

-6.30%
year

Ventyx Biosciences key metrics

Market Cap
159.45M
Enterprise value
1.44B
P/E
-15.9
EV/Sales
N/A
EV/EBITDA
-9.60
Price/Sales
N/A
Price/Book
4.26
PEG ratio
-0.23
EPS
-3.24
Revenue
N/A
EBITDA
-204.06M
Income
-192.60M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Ventyx Biosciences stock price history

Ventyx Biosciences stock forecast

Ventyx Biosciences financial statements

Ventyx Biosciences, Inc. (NASDAQ:VTYX): Profit margin
Jun 2023 0 -53.25M
Sep 2023 0 -54.02M
Dec 2023 1.07M -46.75M -4345.07%
Mar 2024 0 -38.57M
Ventyx Biosciences, Inc. (NASDAQ:VTYX): Analyst Estimates
Mar 2024 0 -38.57M
Sep 2025 0 -40.17M
Oct 2025 0 -34.83M
Dec 2025 0 -34.41M
  • Analysts Price target

  • Financials & Ratios estimates

Ventyx Biosciences, Inc. (NASDAQ:VTYX): Earnings per share (EPS)
2024-05-09 -0.67 -0.62
Ventyx Biosciences, Inc. (NASDAQ:VTYX): Debt to assets
Jun 2023 348763000 20.95M 6.01%
Sep 2023 321701000 38.06M 11.83%
Dec 2023 277693000 33.77M 12.16%
Mar 2024 332078000 25.08M 7.55%
Ventyx Biosciences, Inc. (NASDAQ:VTYX): Cash Flow
Jun 2023 -49.28M 34.81M 2.47M
Sep 2023 -34.66M 38.89M 1.62M
Dec 2023 -51.65M 46.12M 585K
Mar 2024 -47.62M 41.76M 96.18M

Ventyx Biosciences alternative data

Ventyx Biosciences, Inc. (NASDAQ:VTYX): Employee count
Aug 2023 76
Sep 2023 91
Oct 2023 91
Nov 2023 91
Dec 2023 99
Jan 2024 99
Feb 2024 99
Mar 2024 79
Apr 2024 79
May 2024 79
Jun 2024 74
Jul 2024 74

Ventyx Biosciences other data

38.13% -44.46%
of VTYX is owned by hedge funds
20.00M -22.66M
shares is hold by hedge funds

Ventyx Biosciences, Inc. (NASDAQ:VTYX): Insider trades (number of shares)
Period Buy Sel
Apr 2024 0 9019
Nov 2024 500000 0
Dec 2024 130000 13161
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
GUJRATHI SHEILA director
Common Stock 130,000 $2.31 $300,560
Sale
NUSS JOHN officer: CHIEF SCIENTIFIC OFFICER
Common Stock 13,161 $2.26 $29,678
Option
NUSS JOHN officer: CHIEF SCIENTIFIC OFFICER
Common Stock 34,930 N/A N/A
Option
NUSS JOHN officer: CHIEF SCIENTIFIC OFFICER
Restricted Stock Units 34,930 N/A N/A
Option
MOHAN RAJU director, officer: CEO AND PRES..
Common Stock 116,668 N/A N/A
Option
MOHAN RAJU director, officer: CEO AND PRES..
Restricted Stock Units 116,668 N/A N/A
Option
NUSS JOHN officer: CHIEF SCIENTIFIC OFFICER
Common Stock 193,557 $0.2 $38,711
Option
NUSS JOHN officer: CHIEF SCIENTIFIC OFFICER
Common Stock 5,377 $0.2 $1,075
Option
NUSS JOHN officer: CHIEF SCIENTIFIC OFFICER
Stock Option (Right to Buy) 193,557 $0.2 $38,711
Option
NUSS JOHN officer: CHIEF SCIENTIFIC OFFICER
Stock Option (right to buy) 5,377 $0.2 $1,075
Tuesday, 10 December 2024
globenewswire.com
Tuesday, 12 November 2024
globenewswire.com
Monday, 4 November 2024
seekingalpha.com
Tuesday, 24 September 2024
zacks.com
Monday, 23 September 2024
benzinga.com
Friday, 6 September 2024
globenewswire.com
Friday, 30 August 2024
globenewswire.com
Wednesday, 28 August 2024
globenewswire.com
Thursday, 8 August 2024
globenewswire.com
Monday, 29 July 2024
benzinga.com
benzinga.com
Tuesday, 25 June 2024
accesswire.com
globenewswire.com
Monday, 24 June 2024
accesswire.com
Saturday, 22 June 2024
globenewswire.com
Friday, 21 June 2024
accesswire.com
Thursday, 20 June 2024
accesswire.com
globenewswire.com
Wednesday, 19 June 2024
accesswire.com
Tuesday, 18 June 2024
accesswire.com
globenewswire.com
Monday, 17 June 2024
accesswire.com
Friday, 14 June 2024
accesswire.com
Thursday, 13 June 2024
accesswire.com
globenewswire.com
Wednesday, 12 June 2024
accesswire.com
Tuesday, 11 June 2024
accesswire.com
globenewswire.com
Saturday, 8 June 2024
globenewswire.com
Friday, 7 June 2024
accesswire.com
  • What's the price of Ventyx Biosciences stock today?

    One share of Ventyx Biosciences stock can currently be purchased for approximately $2.58.

  • When is Ventyx Biosciences's next earnings date?

    Unfortunately, Ventyx Biosciences's (VTYX) next earnings date is currently unknown.

  • Does Ventyx Biosciences pay dividends?

    No, Ventyx Biosciences does not pay dividends.

  • How much money does Ventyx Biosciences make?

    Ventyx Biosciences has a market capitalization of 159.45M. Ventyx Biosciences made a loss 192.96M US dollars in net income (profit) last year or -$0.62 on an earnings per share basis.

  • What is Ventyx Biosciences's stock symbol?

    Ventyx Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "VTYX".

  • What is Ventyx Biosciences's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Ventyx Biosciences?

    Shares of Ventyx Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Ventyx Biosciences have?

    As Jul 2024, Ventyx Biosciences employs 74 workers, which is 6% less then previous quarter.

  • When Ventyx Biosciences went public?

    Ventyx Biosciences, Inc. is publicly traded company for more then 3 years since IPO on 21 Oct 2021.

  • What is Ventyx Biosciences's official website?

    The official website for Ventyx Biosciences is ventyxbio.com.

  • Where are Ventyx Biosciences's headquarters?

    Ventyx Biosciences is headquartered at 662 Encinitas Boulevard, Encinitas, CA.

  • How can i contact Ventyx Biosciences?

    Ventyx Biosciences's mailing address is 662 Encinitas Boulevard, Encinitas, CA and company can be reached via phone at +7 605934832.

Ventyx Biosciences company profile:

Ventyx Biosciences, Inc.

ventyxbio.com
Exchange:

NASDAQ

Full time employees:

75

Industry:

Biotechnology

Sector:

Healthcare

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

662 Encinitas Boulevard
Encinitas, CA 92024

CIK: 0001851194
ISIN: US92332V1070
CUSIP: 92332V107